While most human T cells express the CD28 costimulatory molecule constitutively, it is well known that age, inflammation, and viral infection can drive the generation of CD28 null T cells. In vitro studies have demonstrated that CD28 null cell effector function is not impacted by the presence of the CD28 costimulation blocker belatacept. As such, a prevailing hypothesis suggests that CD28 null cells may precipitate costimulation blockade-resistant rejection. However, CD28
+ cells possess more proliferative and multifunctional capacity, factors that may increase their ability to successfully mediate rejection. Here, we performed a retrospective immunophenotypic analysis of adult renal transplant recipients who experienced acute rejection on belatacept treatment as compared to those who did not. Intriguingly, our findings suggest that patients possessing higher frequency of CD28 + CD4
+ T EM prior to transplant were more likely to experience acute rejection following treatment with a belatacept-based immunosuppressive regimen. Mechanistically, CD28 + CD4 + T EM contained significantly more IL-2 producers. In contrast, CD28 null CD4 + T EM isolated from stable belatacept-treated patients exhibited higher expression of the 2B4 coinhibitory molecule as compared to those isolated from patients who rejected. These data raise the possibility that pretransplant frequencies of CD28 + CD4 + T EM could be used as a biomarker to predict risk of rejection following treatment with belatacept.
Introduction
Current standard of care immunosuppression for kidney transplantation is focused on the use of calcineurin inhibitors (CNI), and while these reagents are efficacious in inhibiting allograft rejection in the vast majority of patients, they possess a number of off-target effects including nephrotoxicity, hypertension, diabetes, and infectious and malignant complications. Approved by the US Food and Drug Administration in 2011, belatacept has emerged as an alternative to CNI for the prevention of kidney transplant rejection and offers an improved sideeffect profile by targeting CD28 signals important for optimal T cell activation during an alloimmune response. However, both early clinical trials and more recent realworld experience have demonstrated that a subset of patients on belatacept-based regimens experience acute cellular rejection in the first 6 months posttransplant (1, 2) . Transplant practitioners are therefore faced with the challenge of assessing the risk-benefit ratio of these two regimens for individual patients without clinical tools or fundamental knowledge to predict (and possibly mitigate) rejection on belatacept-based regimens.
T cells express myriad inducible costimulatory and coinhibitory receptors during activation and differentiation, and these function to fine-tune the magnitude and character of an immune response (3) (4) (5) (6) (7) . CD28 generates a critical costimulatory signal transduced into T cells following ligation of CD80 and/or CD86 on the surface of antigen-presenting cells (4) . Most T cells express CD28 constitutively; however, in the setting of advanced age or chronic inflammation, humans and nonhuman primates (NHP) accumulate populations of both CD4 + and CD8 + CD28 null cells (8) . Interestingly, emergence of these CD28 null CD4 + and CD8 + T cell populations has been described in the peripheral blood of patients with chronic kidney disease (CKD) (9, 10) . Importantly, patients with kidney failure awaiting transplantation have been described to have variable accumulation of CD28 null CD4 + T cells in peripheral blood (11) (12) (13) (14) . Because belatacept functions to inhibit T cell activation by binding to CD80 and CD86 and thereby preventing CD28-mediated costimulation (15) , it stands to reason that CD28 null cells would be resistant to the effects of belatacept. Indeed, in vitro studies have shown that CD8 addition of belatacept to cell cultures (16) (17) (18) . Based on these data, the prevailing hypothesis in the transplant immunology community is that CD4 + and/or CD8 + CD28 null cells mediate costimulation blockade-resistant rejection (8, 19, 20) (12, 24) . A more recent study similarly found that immunological aging-related expansion of highly differentiated CD4 + CD28 null T cells was associated with a lower risk of acute rejection (25) . In contrast, increased frequency of CD8 + CD28 null cells has been associated with increased rejection in young recipients on CNI therapy (24) , and frequencies of either CD4 + or CD8 + CD28 null T cells failed to predict infectious complications following renal transplantation (26) . Here, we performed a retrospective immunophenotypic analysis of adult renal transplant recipients who experienced acute rejection on belatacept treatment as compared to those who did not. Intriguingly, in contrast to the prevailing (yet untested) hypothesis in the field, our findings suggest that patients possessing higher frequency of CD28 null T cells within the CD4 + or CD8 + T EM compartment prior to transplant were less likely to experience acute rejection following treatment with a belatacept-based immunosuppressive regimen. , a short steroid taper (methylprednisolone 500 mg IV intraoperatively, 250 mg IV d1, 125 mg IV d2, and prednisone 5 mg d3 and daily thereafter), and a tacrolimus taper over the first 3-9 months (target trough levels 5-12 ng/ mL) (27) . The cohort of patients treated with the standard tacrolimusbased regimen (Tac) also included anti-IL-2R induction (basiliximab 20 mg IV on d0 and 3 or 4), MMF (1 g twice daily) and a short steroid taper (methylprednisolone 500 mg IV intraoperatively, 250 mg IV d1, 125 mg IV d2, and prednisone 5 mg d3 and daily thereafter). Patient samples were acquired either prior to transplantation (baseline), or at a follow-up time point 1-5 months posttransplant (for stables) or within 3 days of the diagnosis of acute rejection, before any antirejection treatment was initiated (for rejectors). Rejection refers to biopsy-proven rejection, grade IA or greater as determined by a staff pathologist. Peripheral blood mononuclear cells (PBMCs) were purified from peripheral blood samples via density-gradient centrifugation (cell preparation tubes; BD Pharmingen, Franklin Lakes, NJ) and cryopreserved at À80°C for future intracellular and extracellular staining and analysis via flow cytometry.
Methods

Patient immunosuppression and sample collection
Ex vivo frequency and phenotypic analysis of isolated PBMCs
Standard extracellular staining was performed on PBMCs using the following fluorophore-labeled antibodies: CD14/CD19-V500 (BD Pharmingen), (Biolegend), CD8-BV786 (BD Pharmingen), CD28-PerCP-Cy5.5 (Biolegend), CCR7-PE-Cy7 (Biolegend, San Diego, CA), CD25-APC (Biolegend), CD45RA-qDot655 (Life Technologies, Carlsbad, CA), and CD4-APC-H7 (BD Pharmingen).
Ex vivo intracellular cytokine staining
For determination of ex vivo cytokine production, PBMCs were suspended in 1640 RPMI medium supplemented with 10% heat-inactivated fetal bovine serum, 1% L-glutamine (200 mM), 1% penicillin/streptomycin (100x), 1% N-2-hydroxyethylpiperazine-N 0 -2-ethanesulfonic acid (1M), and 1% 2-mercaptoethanol (14.3M). For T cell stimulation, 1 9 10 6 PBMCs were placed in a 96-well plate and stimulated for 4 h at 37°C with a mixture of phorbol myristate acetate (PMA) (Sigma, St. Louis, MO) and ionomycin (Sigma) at a concentration of 1 lg/mL each. Brefeldin A (GolgiPlug; BD Biosciences) was also added to all cells at a concentration of 1 lg/mL. Intracellular staining was performed after fixation and permeabilization according to manufacturer's instructions (BD Biosciences) utilizing fluorophore-labeled antibodies to interferon-c (IFNc)-fluorescein isothiocyanate and anti-IL-2-AlexaFluor700 (Pharmingen) following extracellular staining as described above.
Statistics
Statistical analysis for flow cytometric assays done with three groups was performed using nonparametric one-way analysis of variance with Prism 5.0 (GraphPad) software. Statistical analysis for flow cytometric assays with two groups was performed using nonparametric two-tailed paired (Wilcoxon) or unpaired (Mann-Whitney) procedures as appropriate with Prism 5.0 (GraphPad) software. Tree analysis was performed with R software. For the clinical data, continuous variables are summarized as median and range and compared using Mann-Whitney U test; categorical variables are expressed as relative and absolute frequencies, and compared using chi-square test. Sensitivity and specificity were calculated using MedCalc. The statistical analysis was performed with SPSS version 21 for Windows (SPSS Inc., Chicago, IL). p-values of <0.05 were considered statistically significant.
Results
Decreased frequencies of CD4 + CD28 null cells at baseline in patients who go on to experience acute rejection on belatacept-based immunosuppression In order to determine immunophenotypic profiles of patients who go on to experience acute rejection following treatment with belatacept versus those who remain stable, we enrolled renal transplant recipients receiving a belatacept-based immunosuppressive regimen at Emory University Hospital in an IRB-approved immune monitoring protocol. PBMC were isolated and banked prior to transplantation (baseline). We then performed a retrospective analysis of immune profiles by flow cytometry of patients who remained stable for the first year following transplant (n = 13) compared to those who went on to experience an episode of acute rejection (n = 10). As shown in Table 1 , stable and rejector cohorts were not different with regard to age, gender, recipient cytomegalovirus status, time on dialysis, or underlying renal disease.
To assess pretransplant CD28 expression patterns within the CD4 + and CD8 + T cell compartments of patients who remained stable following renal transplantation and belatacept-based immunosuppression versus those who did not, PBMC were analyzed by flow cytometry. Data shown are gated on lymphocytes, CD19/CD20 + cells were excluded, and cells were gated based on CD4 and CD8 expression ( Figure 1A ). CD28 expression on these cells was then determined. Surprisingly, pretransplant samples of patients who went on to experience acute rejection while on belatacept exhibited decreased frequencies of CD28 null CD4 + T cells as compared to those who remained stable while on belatacept-based therapy. It is important to note that the frequency of CD28 null CD4 + T cells in stable patients was actually higher than that observed in normal healthy controls ( Figure 1C ), suggesting that the acquisition of increased frequencies of CD28 null CD4 + T cells, potentially as a consequence of CKD, is associated with a more senescent, less alloaggressive immune phenotype. In contrast, patients who went on to experience acute rejection instead possessed increased frequencies of CD28 + CD4 + T cells relative to those who remained stable ( Figure 1C ). The CD28 profiles of CD4 + T cells in these recipients looked more like that of normal healthy controls. Interestingly, these differences at the bulk T cell level were confined to the CD4 + T cell compartment, as no differences in the frequencies of CD28 null cells within the CD8 + T cell compartments of stables versus rejectors were observed ( Figure 1D and E).
Patients who go on to experience belataceptresistant rejection possess increased frequencies of CD28 + CD4 + T EM , CD28 + CD4 + T EMRA , and CD28 + CD8
+ T EM at baseline Based on these initial results, we sought to determine whether the differences in %CD28 + cells within the pretransplant CD4 + T cell compartment in stables versus rejectors could be ascribed to one particular memory T cell subset. PBMCs from the patient cohorts described above were stained with CD45RA and CCR7 to delineate na€ ıve (CD45RA   +   CCR7 + ), central memory (T CM , CD45RAÀ CCR7 + ), effector memory (T EM , CD45RAÀ CCR7À), and effector memory-RA (T EMRA , CD45RA+ CCR7À) subsets. The overall pretransplant frequencies of na€ ıve, T CM , T EM , and T EMRA cells within either the CD4 + or CD8 + T cell compartments were not different between patients who went on to experience acute rejection versus those who did not ( Figure S1A and B) . However, when assessing the frequencies of CD28 + cells within each CD4 + memory T cell subset, we found that the pretransplant frequencies of CD28 + cells among CD4 + na€ ıve cells and CD4 + T CM were similar in patients who went on to reject versus those who did not (Figure 2A and B) . In contrast, the pretransplant frequency of CD28 + cells among CD4 + T EM was very significantly increased in patients who went on to reject versus those who did not (p < 0.0001). We also found a statistically significant increase in the pretransplant frequency of CD28 + cells among CD4 + T EMRA cells in these patients (p = 0.01), although the delineation was not quite as distinct. Frequencies of CD28 + cells among na€ ıve, T CM , T EM , and T EMRA CD4 + T cell compartments in healthy controls are depicted in Figure S2A and B. 
CD28 + CD4 + T EM Predict Rejection on Belatacept
Because we failed to detect any difference in pretransplant CD28 + T cell frequencies in stables versus rejectors within the CD8 + T cell compartment, we next asked whether drilling down into the CD8 + memory T cell subsets would uncover any differences. As was done with the CD4 + compartment above, CD8 + T cells were gated into na€ ıve, T CM , T EM , and T EMRA subsets and the frequencies of CD28 + cells within each of those subsets was determined. These analyses revealed a statistically significant increase in the pretransplant frequency of CD28 + cells within the CD8 + T EM subset in patients who went on to reject versus those who did not (p = 0.05). + T cells in patients who experienced belatacept-resistant rejection (n = 10) versus those who remained stable (n = 13). Pretransplant frequency of CD28 + cells among CD8 + T EM were significantly increased in patients who went on to reject versus those who did not (p = 0.05). *p = 0.05, **p = 0.01, ***p < 0.0001.
Frequencies of CD28
+ cells among na€ ıve, T CM , T EM , and T EMRA CD8 + T cell compartments in healthy controls are depicted in Figure S2C and D.
Frequency of CD28
+ CD4 + T EM fails to stratify stables versus rejectors among tacrolimus-treated renal transplant recipients Given the above results, we next sought to determine whether this signature of higher frequencies of CD28 + CD4
+ T EM also functioned to stratify risk of rejection in patients treated with calcineurin inhibitor-based immunosuppression. As such, we assessed pretransplant immune profiles in 15 patients who had previously undergone renal transplantation at Emory University Hospital and had been enrolled in an IRB-approved immune monitoring protocol ( Table 2) . In contrast to what we observed in patients who received belatacept-based immunosuppression, both pretransplant %CD28
+ of CD4 + and %CD28 + of CD4 + T EM failed to stratify rejectors (n = 7) versus stables (n = 8) in patients who received tacrolimus-based immunosuppression ( Figure 3A and B) . Likewise, pretransplant assessment of the frequencies of CD28 + CD8 + T cells, either in the bulk or T EM compartment, also failed to correlate with risk of rejection ( Figure 3C and D + T EM subsets (both subsets were isolated from normal healthy controls). PBMC were stimulated ex vivo with PMA/ionomycin as described in the Methods section, and CD4 + cells were gated on CD28 + versus CD28 À and analyzed for IFN-c and IL-2 production. As shown in Figure 4A , a high frequency of CD28 null CD4 + T cells secreted IFN-c, but virtually no cells were capable of secreting IL-2, a critical T cell growth factor. In contrast, CD28 + CD4 + T cells were capable of secreting both IFN-c and IL-2 (Figure 4A-C) . Thus, these data demonstrate that CD28 null CD4 + T cells may be defective in their capacity to execute a successful rejection response driven by IL-2. Given these differences in the functional capacities of CD28 null versus CD28 + CD4 + T cell subsets, we hypothesized that CD4 + populations isolated from stables versus rejectors would exhibit differential cytokine production. To test this, pretransplant PBMC from stables versus rejectors were restimulated ex vivo and IFN-c and IL-2 production was assessed. Stables and rejectors did not differ with regard to the frequencies of IFN-c-secreting cells within their CD4 + T cell compartments ( Figure 4D ). However, patients who went on to reject exhibited a statistically significantly higher frequency of IL-2-secreting CD4 + T cells as compared to patients who experienced freedom from rejection ( Figure 4E ). Data from our complementary NHP studies have also revealed an enrichment of CD28 null cells in rejecting allografts, suggesting that these may be the cells that actually mediate costimulation blockade-resistant rejection. We next queried the extent of CD28 downregulation following TCR stimulation in CD28 + CD4 + T EM in stables versus rejectors. Following ex vivo stimulation with PMA/ionomycin, CD4 + T cell populations from rejectors, Figure 4G ). This rapid emergence of a CD28 null CD4 + T cell population was not observed in pretransplant CD4 + T cell populations isolated from stable recipients (Figure 4F ). These data demonstrate that CD28 + T cell populations are capable of rapidly generating a CD28 null component following TCR stimulation, as would be the case upon in vivo encounter with antigen.
CD28
null CD4 + T EM isolated from stables but not rejectors expressed increased levels of the coinhibitory molecule 2B4 We next sought to identify phenotypic markers in CD28 null CD4 + T cell populations that might underlie the observed deficiency of these cells to optimally produce IL-2. Importantly, CD28 null CD4 + T cells were found to exhibit high expression of the T cell coinhibitory molecule 2B4 ( Figure 5A ). 2B4 is a member of the CD2 family and associates intracellularly with SHP-1 phosphatases to dampen T cell responses (28, 29) , and we recently reported that upregulation of 2B4 was functionally important for the efficacy of CD28 costimulation blockade to inhibit alloreactive T cell responses in a murine model of transplantation (30) . In this cohort of human renal transplant recipients, 2B4 expression was low (%5-10%) on CD28 + CD4 + T EM , and was not different between stable patients and rejectors ( Figure 5B ). In contrast, stable patients exhibit statistically significantly higher expression of 2B4 on CD28 null CD4 + T cells compared to either rejectors or to healthy controls ( Figure 5C ). We observed no differences in the expression of coinhibitory molecules PD-1 and TIM-3 on CD28 null CD4 + T cells in stables compared to rejectors (data not shown). These data suggest that upregulation of 2B4 on CD28 null CD4 + T cells is associated with freedom from rejection following treatment with belatacept. increased pretransplant frequencies of CD28 null CD4 + T EM relative to normal healthy controls. We thus queried whether end-stage renal disease (ESRD) is a driver of the CD28 null CD4 + T EM phenotype. We identified a statistically significant increase in CD28 null cells in ESRD patients as compared to normal healthy controls within the CD4 + T cell compartment ( Figure 6A ). In contrast, CD28 null cells were not increased within the CD8 + T cell compartment of ESRD patients as compared to normal healthy controls ( Figure 6B ). In order to determine whether this increase in CD4 + CD28 null cells was common to chronic, end-stage organ failure diseases or was specific to ESRD, we interrogated the CD28 phenotypes in a cohort of end-stage liver disease (ESLD) patients awaiting liver transplantation (cohort characteristics described in Table S1 ). Interestingly, ESLD patients also exhibited a significant increase in CD28 null CD4 + (Figure 6A) but not CD28 null CD8 + T cells ( Figure 6B ) relative to healthy controls, suggesting that the inflammatory milieu and immune dysregulation associated with ESLD also drives accumulation of CD28 null CD4 + T cells in some patients. Fifty-five percent of this cohort of patients awaiting liver transplant exhibited frequencies of CD28 + CD4 + T EM similar to those observed in the cohort of renal transplant recipients who experienced rejection on belatacept ( Figure 6C ). 
Discussion
In this study, we retrospectively assessed immune profiles of belatacept-treated renal transplant recipients who went on to experience acute rejection following transplantation versus those who did not, and identified a population of CD28 + CD4 + T EM that was significantly increased in pretransplant PBMC samples isolated from rejectors versus stables. These data suggest that pretransplant frequency of CD28 + cells within the CD4 + T EM subset could be used as a predictive biomarker to identify patients who are at increased risk of rejection with a belatacept-based immunosuppressive regimen. Because this test can be easily run by any clinical flow cytometry laboratory (as opposed to more onerous tests for donorspecific memory T cells that are currently not able to be performed at all transplant centers), it may be a useful addition to the transplant diagnostic armamentarium. Based on the data from this initial cohort, this biomarker would be predicted to have high sensitivity, in that 100% of patients who went on to experience rejection fell above the 83.6% cutoff for CD28 + cells as a percentage of CD4 + T EM . However, this methodology would be predicted to classify 20% of rejectors as stables (i.e. a 20% false-negative rate). Still, the potential promise of this biomarker to identify and eliminate 80% of patients who would go on to experience belatacept-resistant rejection warrants further testing in a larger, prospective cohort of renal transplant recipients.
While our data detected an association between high frequencies of CD28 + CD4 + T EM and rejection, the study of course does not necessarily demonstrate a causal link between this population and the precipitation of rejection. Still, it is important to note that several mechanistic studies support a role for this cell type in mediating, or being associated with, belatacept-resistant rejection. For example, Espinosa et al described a subset of CD57-expressing CD4 + T EM that were associated with increased incidence of rejection while on belatacept (but not tacrolimus) treatment (19) (28, (31) (32) (33) (34) , and a recent study that defined the cells that restore the immune response following PD-1 blockade identified them as being 2B4 precursor frequency is a critical determinant of susceptibility versus resistance to a costimulation blockadebased regimen (36) . On the other hand, an alternative hypothesis is that 2B4 + CD28 null CD4 + T EM are functioning to suppress the donor-specific immune response. Future studies are aimed at investigating these possibilities.
While our study identified a biomarker that is potentially predictive of rejection while on a belatacept-containing regimen, it is important to consider that patients in this cohort also received tacrolimus at early time points following transplantation, weaning at 3-9 months posttransplant (27) . Many patients rejected during this wean period, leading us to conclude that these rejection episodes are precipitated by costimulation-independent T cell populations that become activated as CNI levels decline. Indeed, in our study the relative frequency of CD28 + CD4 + T EM did not segregate rejectors versus stables in tacrolimus-treated patients. Furthermore, our conclusion that the frequency of CD28 + CD4 + T EM is a biomarker specific to belatacept-resistant rejection is validated by a contemporaneous NHP study in which rhesus macaque renal transplant recipients that went on to experience rejection following treatment with a tacrolimus-free belatacept-containing regimen exhibited higher frequencies of CD28 + CD8 + memory T cells relative to nonrejecting controls (37) . Similar to our human study, this association of CD28 + memory T cells with rejection was not observed in the tacrolimus-treated control arm. Taken together, these data suggest that the mechanisms of rejection at play in recipients containing high pretransplant frequencies of CD28 + CD4 + T EM are likely effectively controlled by calcineurin inhibition. Identifying other immunologic pathways critical for recall responses in these CD28-independent populations remains an important step toward the goal of developing CNI-free treatment regimens for these patient populations.
As mentioned above, complementary data from a rhesus macaque model of renal transplantation also identified increased frequencies of CD28 + memory T cells as being predictive of belatacept-resistant rejection; however, in this study the difference was localized to the CD8 + T EMRA subset. While our study did identify a statistically significant increase in CD28 + T EM in human rejectors versus stable patients, the biggest differences were observed in the CD4 + T cell compartment. This difference between the NHP and human data may be related to the fact that the NHP recipients are immunologically more akin to healthy controls than uremic patients experiencing years of CKD, which our data show results in an increase in the frequencies of CD4 + but not CD8 + CD28 null cells relative to human controls ( Figure 6 ). These data highlight the complex nature of modeling the immunology of renal transplant recipients using animal systems, and suggest that recapitulating the uremic environment of CKD in animal models may shed new light on alloimmunity and the mechanisms of allograft rejection.
Finally, it is interesting to note that similar to the increase in CD4 + CD28 null cells observed in ESRD patients awaiting kidney transplantation, a subset of ESLD patients awaiting liver transplantation also exhibited a significant increase in the frequency of CD28 + CD4 + T EM cells relative to normal healthy controls. The mechanisms underlying belatacept-resistant rejection in liver transplantation is an important area of research, because while on the surface the relative ease of tolerization may make liver transplantation seem like an ideal context for use of belatacept, early clinical trials of belatacept in liver transplantation revealed markedly high rates of rejection (47% in the belatacept treated arm versus 9% in the control CNI-treated arm) (38) . Thus, while the mechanisms of belatacept-resistant rejection during liver transplantation remain an important area of investigation, it is interesting to speculate that the frequency of CD28 + CD4 + T EM could also be used as a biomarker to predict risk of rejection of liver transplant recipients following treatment with belatacept treatment, potentially paving a path to clinical implementation of belatacept in a select subset of liver transplant recipients with the most "permissive" immune profiles. In sum, our data offer insight into the immunologic environments associated with belataceptresistant rejection in human renal transplant recipients and demonstrate an example of how pretransplant immune profiling may allow for personalized immunotherapy to improve outcomes following transplantation. Figure S1: The overall pretransplant frequencies of na€ ıve, TCM, TEM, and TEMRA cells within both the CD4+ (A) and CD8+ (B) T cell compartments were not different between patients who went on to experience acute rejection versus those that did not. Figure S2 : The frequencies of na€ ıve, TCM, TEM, and TEMRA cells within both the CD4+ (A and B) and CD8+ (C and D) T cell compartments of healthy control subjects (n = 5) are depicted. 
